Exonhit says EHT 0202 could be 'major therapeutic breakthrough' in Alzheimer's and other dementias

PARIS (Thomson Financial) - ExonHit Therapeutics' EHT 0202 compound could be a 'major therapeutic breakthrough' in the treatment of Alzheimer's disease, the company said.
In a preview of a presentation to be given at the International Conference on Alzheimer's Disease in Chicago from July 26 to 31, ExonHit said it is developing two proprietary programmes in Alzheimer's disease.
EHT 0202, currently in phase II of clinical trials, is based on a mechanism to redirect the processing of APP (Amyloid Precursor Protein), which is pivotal in the evolution of Alzheimer's disease, the company said.
The second programme, EHT 206, is in pre-clinical stage and focuses on the development of chemical entities aiming at inhibiting the formation of senile plaques, largely composed of aggregated beta amyloid peptides, the company said.
These plaques play a major role in the loss of cognitive functions in patients suffering from Alzheimer's disease, it said.

for more about this click here

More info click here